Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study (Q40340899)
Jump to navigation
Jump to search
scientific article published on 13 December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study |
scientific article published on 13 December 2010 |
Statements
1 reference
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study (English)
1 reference
Michael Andersson
1 reference
Elisabeth Lidbrink
1 reference
Karsten Bjerre
1 reference
Erik Wist
1 reference
Kristin Enevoldsen
1 reference
Anders B Jensen
1 reference
Per Karlsson
1 reference
Ulla B Tange
1 reference
Peter G Sørensen
1 reference
Susanne Møller
1 reference
Jonas Bergh
1 reference
Sven T Langkjer
1 reference
13 December 2010
1 reference
1 reference
Identifiers
1 reference